Psychobiology Section, National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, 251 Bayview Blvd, Baltimore, MD 21224, USA.
Psychopharmacology (Berl). 2013 Feb;225(3):733-42. doi: 10.1007/s00213-012-2862-2. Epub 2012 Sep 14.
Previous studies have demonstrated that several N-substituted 4', 4″-diF-benztropine (BZT) analogs with high dopamine transporter affinity selectively decreased cocaine self-administration without affecting food-maintained behavior in rats.
The present study examined if the decreases in cocaine self-administration are due to competition from excess behavioral activity (hyperlocomotion or stereotypy) induced by the BZT analogs alone or in combination with cocaine.
Pretreatments with the typical dopamine uptake inhibitor methylphenidate [1.0, 3.2, and 10 mg/kg, intraperitoneally (i.p.)] dose-dependently shifted the cocaine self-administration dose-effect curve (0, 0.032, 0.1, 0.32, and 1.0 mg/kg/injection) leftward. The shift in the dose-effect curve was obtained at doses of methylphenidate that, when administered alone, also decreased food-maintained behavior and increased locomotor activity and stereotypy. In contrast, the N-substituted BZT analogs, JHW 007 (1.0, 3.2, and 10 mg/kg, i.p.), AHN 1-055 (10 mg/kg), and, AHN 2-005 (10 mg/kg), as previously reported, decreased the maximum for the cocaine self-administration dose-effect curve, and did so at doses that were virtually without effects on food-maintained behavior. Further, the BZT analogs alone had minimal effects on locomotor activity and stereotypies and did not appreciably change the effects of cocaine on these measures when administered in combination with cocaine.
The present results suggest that the decrease in cocaine self-administration produced by the N-substituted BZT analogs is due to an antagonism of the reinforcing effects of cocaine rather than due to interference from competing behavioral overstimulation, and further supports the development of N-substituted BZT analogs as medications to treat cocaine abuse.
先前的研究表明,几种具有高多巴胺转运体亲和力的 N-取代 4',4″-二 F-苯托品(BZT)类似物选择性地降低可卡因的自我给药,而不会影响大鼠的食物维持行为。
本研究检查了可卡因自我给药的减少是否是由于 BZT 类似物单独或与可卡因联合引起的过量行为活动(过度运动或刻板行为)的竞争所致。
典型的多巴胺摄取抑制剂哌醋甲酯[1.0、3.2 和 10mg/kg,腹膜内(i.p.)]预处理剂量依赖性地使可卡因自我给药剂量-效应曲线(0、0.032、0.1、0.32 和 1.0mg/kg/注射)向左移位。剂量-效应曲线的移位发生在哌醋甲酯给药剂量下,这些剂量单独给药时也会减少食物维持行为并增加运动活动和刻板行为。相比之下,如前所述,N-取代的 BZT 类似物 JHW 007(1.0、3.2 和 10mg/kg,i.p.)、AHN 1-055(10mg/kg)和 AHN 2-005(10mg/kg)降低了可卡因自我给药剂量-效应曲线的最大值,并且在实际上对食物维持行为没有影响的剂量下做到了这一点。此外,BZT 类似物单独对运动活动和刻板行为的影响很小,并且当与可卡因联合给药时,不会明显改变可卡因对这些措施的影响。
本研究结果表明,N-取代的 BZT 类似物降低可卡因自我给药是由于对可卡因的强化作用的拮抗作用,而不是由于竞争行为过度刺激的干扰,进一步支持了 N-取代的 BZT 类似物作为治疗可卡因滥用的药物的开发。